A Phase 3 interventional study of ENZ215 and Prolia in Postmenopausal Osteoporosis, sponsored by Enzene Biosciences Ltd.. Completed at 48 sites in 7 countries. Open to female participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-02-10.
Sponsored by Enzene Biosciences Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Osteoporosis, Postmenopausal with a site in Poland — none open to participants now, 2 under way, 1 of them phase 3. Osteoporosis, Postmenopausal · Poland.
Among the 36 studies in Osteoporosis, Postmenopausal with a site in Poland, this one is the 22nd largest by enrollment, is one of 4 that started in 2022, is one of 27 in phase 3, and was the 32nd registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →None of the 36 studies in Osteoporosis, Postmenopausal with a site in Poland is open now. The open studies under Osteoporosis, Postmenopausal, anywhere →
Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 55 Years to 85 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 1994; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 504 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 543 across the 36 interventional studies. Of the 34 that completed or were terminated, 29 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 36 have an industry lead sponsor. The 10 most frequent:
Enzene Biosciences Ltd. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Enzene Biosciences Ltd. has 1 study filed under Osteoporosis, Postmenopausal — fewer than ten, so there is no comparison to draw.
1 of the studies in Osteoporosis, Postmenopausal with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06577935Angitia BiopharmaceuticalsA Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS) | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies in Osteoporosis, Postmenopausal with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Study will be conducted to Compare the Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Enzene Denosumab (ENZ215) and Prolia® in Postmenopausal Women with Osteoporosis.
The primary goal for the study is
The study will be divided into three periods: Screening period: up to 35 days; Double-blind treatment period of 12 months; and Open-label, switch-over period of six months.
Five hundred four (504) patients (252 patients in each treatment arm) will be enrolled in this study. All eligible patients will be randomized in the double blind treatment period in a 1:1 ratio to receive either ENZ215 or Prolia® (60 mg) subcutaneously (SC) on Day 1 and Month 6. These participants will complete study at 12 months. A PK sub-study will be conducted in a subset of 120 participants with 60 participants in each arm.
A subset of 120 participants randomised to Prolia arm and who completed 12 months of the double-blind treatment period without any significant safety concerns per the Investigator's discretion will be offered to enroll in the open-label, switch-over extension period. After re-consenting for the open-label, switch-over study, the participants will be re-randomised in a 1:1 ratio to receive either ENZ215 or Prolia® (60 mg) SC at Month 12. These participants will complete the study at Month 18.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
women aged ≥ 55 and ≤ 85 years globally, except for Spain. In Spain specifically refer to the below criteria:
Exclusion Criteria:
Previous use of oral bisphosphonates:
Other bone active drugs (i.e. drugs affecting bone metabolism) including heparin, anti epileptics (except for benzodiazepines and pregabalin), antidepressants such as SSRIs, SNRIs, antipsychotics, systemic ketoconazole, adrenocorticotrophic hormone (ACTH), lithium, protease inhibitors, gonadotropin releasing hormone (GnRH) agonists, or anabolic steroids within the past 3 months prior to screening or requiring treatment with these agents during the study.
Note: Please refer to Section 6.11 for a comprehensive list of prohibited medications
Oral or dental conditions:
Patient with an active infection or history of infection as follows:
Evidence of any of the following conditions per laboratory test results, medical history, (ECG), DXA, or X-ray review:
i. History of cardiac arrhythmia or long syndrome or ECG abnormalities at screening indicating significant risk for safety (e.g., that required hospitalization, emergency cardioversion, or defibrillation) ii. History and/or presence of myocardial infarction within 6 months before screening iii. History and/or presence of (NYHA) class III or IV heart failure
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ENZ215 Injection: - 60 mg denosumab administered as a single subcutaneous injection at day 1 and at month 6
Biological: ENZ215
Prolia Injection: - 60 mg denosumab administered as a single subcutaneous injection at day 1 and at month 6
Biological: Prolia
Enrolled women with postmenopausal osteoporosis receive ENZ215 (60mg)
Enrolled women with postmenopausal osteoporosis receive Prolia
To Evaluate the Efficacy of ENZ215 When Compared to Prolia in Patients With Postmenopausal Osteoporosis, in Terms of Change in Bone Mineral Density (BMD) at Lumbar Spine.
The percentage change in BMD at lumbar spine (L1-L4 region) measured by DXA from baseline to month 12 and the mean (±SD) percentage change over time is displayed for the ITT set. The ITT analysis set consisted of all randomised participants who received at least one dose of study intervention in the double-blind treatment period. In the ITT analysis set, treatment was assigned based on the study intervention to which participants were randomised, regardless of which treatment they actually received.
Time frame: Month 12
Area Under the Effect Curve (AUEC) of % Change From Baseline (%CfB) of Serum C-telopeptide of Type-1 Collagen (sCTX) Levels
The AUEC of %CfB in sCTX of ENZ215 was assessed as part of pharmacodynamics assessment to compare with Prolia® in female participants with postmenopausal osteoporosis. This outcome measure was assessed for initial 6 months
Time frame: Month 6
To Compare the Immunogenicity Potential of ENZ215 and Prolia
ADAs incidence such as ADA positive, ADA negative, NAB positive, NAB negative assessed at baseline and different timepoints from 1 month to 12 months and during open-label switch over period assessed. Subjects were considered as post-treatment ADA and NAb positive if they had at least one "Positive" ADA and NAb result after the first drug exposure. Post-treatment ADA and NAb status was determined regardless of the results at pre-dose.
Time frame: From Baseline to Month 12 for Double blind treatment period and to month 18 for Open label switchover treatment period
To Compare the Pharmacokinetics of ENZ215 and Prolia
Comparison of PK parameters of ENZ215 and Prolia over 12 months
Time frame: 12 months
Serum Procollagen Type 1 N-terminal Propeptide (sP1NP) Levels
Percent change from baseline in type 1 N-terminal propeptide (sP1NP) levels at 6 months
Time frame: Month 6
To Compare the Change in BMD at the Lumbar Spine at Month 6
Percentage change in BMD at lumbar spine measured by DXA from baseline at month 6
Time frame: Baseline to Month 6
To Compare the Change in BMD at Total Hip and Femoral Neck
Percentage change in BMD at total hip and femoral neck measured by DXA from baseline to Month to predefined timepoint
Time frame: Baseline to Month 6 and Month 12
A total of 504 participants were randomized in the study at 44 centers across 7 countries (Bulgaria, Czech Republic, Denmark, Lithuania, Poland, Spain and Serbia) between July 2022 and January 2023.
| Milestone | ENZ215 | Prolia | Prolia + ENZ215 | Prolia + Prolia |
|---|---|---|---|---|
| Started | 253 | 251 | 0 | 0 |
| Completed | 233 | 236 | 0 | 0 |
| Not completed | 20 | 15 | 0 | 0 |
| Milestone | ENZ215 | Prolia | Prolia + ENZ215 | Prolia + Prolia |
|---|---|---|---|---|
| Started | 0 | 0 | 60 | 60 |
| Completed | 0 | 0 | 60 | 60 |
| Not completed | 0 | 0 | 0 | 0 |
The percentage change in BMD at lumbar spine (L1-L4 region) measured by DXA from baseline to month 12 and the mean (±SD) percentage change over time is displayed for the ITT set. The ITT analysis set consisted of all randomised participants who received at least one dose of study intervention in the double-blind treatment period. In the ITT analysis set, treatment was assigned based on the study intervention to which participants were randomised, regardless of which treatment they actually received.
| % Change from Baseline | ENZ215 | Prolia |
|---|---|---|
| To Evaluate the Efficacy of ENZ215 When Compared to Prolia in Patients With Postmenopausal Osteoporosis, in Terms of Change in Bone Mineral Density (BMD) at Lumbar Spine. | 5.350 ± 0.3152 | 5.533 ± 0.3108 |
The AUEC of %CfB in sCTX of ENZ215 was assessed as part of pharmacodynamics assessment to compare with Prolia® in female participants with postmenopausal osteoporosis. This outcome measure was assessed for initial 6 months
| h*% | ENZ215 | Prolia |
|---|---|---|
| Area Under the Effect Curve (AUEC) of % Change From Baseline (%CfB) of Serum C-telopeptide of Type-1 Collagen (sCTX) Levels | 347382.787 (340087.2488 to 354834.8289) | 345858.423 (338640.7259 to 352229.9557) |
ADAs incidence such as ADA positive, ADA negative, NAB positive, NAB negative assessed at baseline and different timepoints from 1 month to 12 months and during open-label switch over period assessed. Subjects were considered as post-treatment ADA and NAb positive if they had at least one "Positive" ADA and NAb result after the first drug exposure. Post-treatment ADA and NAb status was determined regardless of the results at pre-dose.
| Participants | ENZ215 | Prolia | Prolia + ENZ215 | Prolia + Prolia |
|---|---|---|---|---|
| ADA positive subjects | 252 | 247 | 60 | 60 |
| nAb positive subjects | 1 | 5 | 0 | 0 |
| ADA Negative | 0 | 0 | 0 | 0 |
| Nab Negative | 251 | 242 | 60 | 60 |
Comparison of PK parameters of ENZ215 and Prolia over 12 months
| h*ng/mL | ENZ215 | Prolia |
|---|---|---|
| AUC (0-1M) | 3220000 ± 40.4 | 3000000 ± 33.1 |
| AUC (0-3M) | 7260000 ± 45.7 | 6450000 ± 35.2 |
| AUC (0-6M) | 8420000 ± 48.0 | 7460000 ± 36.7 |
| AUC (6-12M) | 312000 ± 232.1 | 301000 ± 130.5 |
Percent change from baseline in type 1 N-terminal propeptide (sP1NP) levels at 6 months
| Percentage Change from baseline | ENZ215 | Prolia |
|---|---|---|
| Month 1 (Day 15) | 8.3369 ± 19.5170 | 7.5198 ± 17.9673 |
| Month 1 (Day 30) | -17.7485 ± 17.1910 | -18.3767 ± 23.4844 |
| Month 3 (Day 90) | -75.7738 ± 15.4099 | -74.5419 ± 16.6630 |
| Month 6 (Day 180) | -69.7567 ± 19.4086 | -69.1690 ± 22.8816 |
Percentage change in BMD at lumbar spine measured by DXA from baseline at month 6
| Percentage Change | ENZ215 | Prolia |
|---|---|---|
| To Compare the Change in BMD at the Lumbar Spine at Month 6 | 3.615 ± 0.2643 | 4.004 ± 0.2596 |
Percentage change in BMD at total hip and femoral neck measured by DXA from baseline to Month to predefined timepoint
| Percentage Change | ENZ215 | Prolia |
|---|---|---|
| Month 6-BMD at Total Hip | 2.222 ± 0.2042 | 2.327 ± 0.2005 |
| Month 6-BMD at Femoral Neck | 1.700 ± 0.2461 | 1.688 ± 0.2420 |
| Month 12-BMD at Total Hip | 2.534 ± 0.2044 | 2.935 ± 0.2012 |
| Month 12-BMD at Femoral Neck | 1.826 ± 0.2905 | 2.589 ± 0.2866 |
Collected over From Baseline to Month 12 for participants in main study and up to 18 months for participants in Open label switch over period. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ENZ215 | 0/253 (0%) | 16/253 (6.3%) | 115/253 (45.5%) |
| Prolia | 1/251 (0.4%) | 15/251 (6%) | 122/251 (48.6%) |
| Prolia + ENZ215 | 0/60 (0%) | 0/60 (0%) | 23/60 (38.3%) |
| Prolia + Prolia | 0/60 (0%) | 0/60 (0%) | 23/60 (38.3%) |
| Event | ENZ215 | Prolia | Prolia + ENZ215 | Prolia + Prolia |
|---|---|---|---|---|
| Radius FractureInjury, poisoning and procedural complications | 3/253 | 1/251 | 0/60 | 0/60 |
| Wrist FractureInjury, poisoning and procedural complications | 2/253 | 0/251 | 0/60 | 0/60 |
| Ankle FractureInjury, poisoning and procedural complications | 1/253 | 1/251 | 0/60 | 0/60 |
| Craniofacial fractureInjury, poisoning and procedural complications | 0/253 | 1/251 | 0/60 | 0/60 |
| Foot FractureInjury, poisoning and procedural complications | 0/253 | 1/251 | 0/60 | 0/60 |
| Forearm FractureInjury, poisoning and procedural complications | 0/253 | 1/251 | 0/60 | 0/60 |
| Lower Limb FractureInjury, poisoning and procedural complications | 0/253 | 1/251 | 0/60 | 0/60 |
| COVID-19Infections and infestations | 0/253 | 1/251 | 0/60 | 0/60 |
| CystitisInfections and infestations | 0/253 | 1/251 | 0/60 | 0/60 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/253 | 1/251 | 0/60 | 0/60 |
| Event | ENZ215 | Prolia | Prolia + ENZ215 | Prolia + Prolia |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 18/253 | 22/251 | 5/60 | 5/60 |
| Upper Respiratory Tract InfectionInfections and infestations | 11/253 | 16/251 | 2/60 | 0/60 |
| HeadacheNervous system disorders | 6/253 | 13/251 | 0/60 | 0/60 |
| HypertensionVascular disorders | 9/253 | 12/251 | 0/60 | 0/60 |
| COVID-19Infections and infestations | 5/253 | 12/251 | 1/60 | 1/60 |
| BronchitisInfections and infestations | 11/253 | 6/251 | 0/60 | 2/60 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 9/253 | 9/251 | 0/60 | 0/60 |
| Spinal PainMusculoskeletal and connective tissue disorders | 5/253 | 4/251 | 2/60 | 0/60 |
| PharyngitisInfections and infestations | 6/253 | 3/251 | 2/60 | 0/60 |
| Urinary Tract InfectionInfections and infestations | 8/253 | 8/251 | 0/60 | 0/60 |
Postmenopausal Women with Osteoporosis aged ≥ 55 and ≤ 85 years
| Age, Categorical(Participants) | ENZ215 | Prolia | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 171 | 171 | 342 |
| >=65 years | 82 | 80 | 162 |
| Sex: Female, Male(Participants) | ENZ215 | Prolia | Total |
|---|---|---|---|
| Female | 253 | 251 | 504 |
| Male | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | ENZ215 | Prolia | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 253 | 251 | 504 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2022 to primary completion in Jul 2024, 24 months.
Results were first posted in Feb 2026, 1 year 6 months after primary completion.
Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 24 months is close to that.
Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Osteoporosis, Postmenopausal →
Enzene Biosciences Ltd.